共 50 条
- [21] ADRIAMYCIN (NSC-123127) - MODE AND MECHANISM OF ACTION CANCER CHEMOTHERAPY REPORTS PART 3 PROGRAM INFORMATION-SUPPLEMENT, 1975, 6 (02): : 91 - 106
- [22] POLYCHEMOTHERAPY WITH ADRIAMYCIN (NSC-123127) IN BRONCHOGENIC CARCINOMA CANCER CHEMOTHERAPY REPORTS PART 3 PROGRAM INFORMATION-SUPPLEMENT, 1975, 6 (02): : 353 - 359
- [23] PRELIMINARY PHARMACOKINETIC MODEL FOR ADRIAMYCIN (NSC-123127) CANCER CHEMOTHERAPY REPORTS PART 1, 1975, 59 (04): : 819 - 825
- [24] SOME OBSERVATIONS ON TOXICITY OF ADRIAMYCIN (NSC-123127) CANCER CHEMOTHERAPY REPORTS PART 3 PROGRAM INFORMATION-SUPPLEMENT, 1975, 6 (02): : 177 - 181
- [25] USE OF ADRIAMYCIN (NSC-123127) IN HEMATOLOGIC MALIGNANCIES CANCER CHEMOTHERAPY REPORTS PART 3 PROGRAM INFORMATION-SUPPLEMENT, 1975, 6 (02): : 369 - 373
- [26] ADRIAMYCIN (NSC-123127) IN 87 PATIENTS WITH OSTEOSARCOMA CANCER CHEMOTHERAPY REPORTS PART 3 PROGRAM INFORMATION-SUPPLEMENT, 1975, 6 (02): : 305 - 313
- [27] ADRIAMYCIN (NSC-123127) CARDIOTOXICITY - CLINICOPATHOLOGIC CORRELATION CANCER CHEMOTHERAPY REPORTS PART 3 PROGRAM INFORMATION-SUPPLEMENT, 1975, 6 (02): : 215 - 225
- [28] CURRENT STATUS OF STUDIES WITH ADRIAMYCIN (NSC-123127) CANCER CHEMOTHERAPY REPORTS PART 3 PROGRAM INFORMATION-SUPPLEMENT, 1973, 4 (03): : 47 - 50
- [29] UNCOMMON SIDE-EFFECTS OF ADRIAMYCIN (NSC-123127) CANCER CHEMOTHERAPY REPORTS PART 1, 1974, 58 (06): : 757 - 758
- [30] RATIONAL BASES FOR ADRIAMYCIN (NSC-123127) COMBINATION THERAPY CANCER CHEMOTHERAPY REPORTS PART 3 PROGRAM INFORMATION-SUPPLEMENT, 1975, 6 (02): : 227 - 230